The potential effect of HBV vaccination on off-treatment HBsAg reversion after interferon-induced HBsAg clearance

References

• Razavi-Shearer D, Gamkrelidze I, Nguyen MH, Chen D-S, Van Damme P, Abbas Z, Abdulla M, Abou Rached A, Adda D, Aho I, et al. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. Lancet Gastroenterol Hepatol. 2018;3(6):383–10. doi:10.1016/s2468-1253(18)30056-6.
   PubMed Web of Science ®Google Scholar
• Wong MCS, Huang JLW, George J, Huang J, Leung C, Eslam M, Chan HLY, Ng SC. The changing epidemiology of liver diseases in the Asia–Pacific region. Nat Rev Gastroenterol Hepatol. 2019;16(1):57–73. doi:10.1038/s41575-018-0055-0.
   PubMed Web of Science ®Google Scholar
• Sarin SK, Kumar M, Lau GK, Abbas Z, Chan HL, Chen CJ, Chen DS, Chen HL, Chen PJ, Chien RN, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2016;10(1):1–98. doi:10.1007/s12072-015-9675-4.
   PubMed Web of Science ®Google Scholar
• Omata M, Cheng AL, Kokudo N, Kudo M, Lee JM, Jia J, Tateishi R, Han KH, Chawla YK, Shiina S, et al. Asia–pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int. 2017;11(4):317–70. doi:10.1007/s12072-017-9799-9.
   PubMed Web of Science ®Google Scholar
• Kao JH, Jeng WJ, Ning Q, Su TH, Tseng TC, Ueno Y, Yuen MF. APASL guidance on stopping nucleos(t)ide analogues in chronic hepatitis B patients. Hepatol Int. 2021;15(4):833–51. doi:10.1007/s12072-021-10223-5.
   PubMed Web of Science ®Google Scholar
• EASL. Clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67(2):370–98. doi:10.1016/j.jhep.2017.03.021.
   PubMed Web of Science ®Google Scholar
• Terrault NA, Lok ASF, McMahon BJ, Chang KM, Hwang JP, Jonas MM, Brown RS Jr., Bzowej NH, Wong JB. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67(4):1560–99. doi:10.1002/hep.29800.
   PubMed Web of Science ®Google Scholar
• Song A, Lin X, Chen X. Functional cure for chronic hepatitis B: accessibility, durability, and prognosis. Virol J. 2021;18(1):114. doi:10.1186/s12985-021-01589-x.
   PubMed Web of Science ®Google Scholar
• Marcellin P, Ahn SH, Ma X, Caruntu FA, Tak WY, Elkashab M, Chuang WL, Lim SG, Tabak F, Mehta R, et al. Combination of tenofovir disoproxil fumarate and peginterferon α-2a increases loss of hepatitis B surface antigen in patients with chronic hepatitis B. Gastroenterology. 2016;150(1):134–44.e110. doi:10.1053/j.gastro.2015.09.043.
   PubMed Web of Science ®Google Scholar
• Ren P, Cao Z, Mo R, Liu Y, Chen L, Li Z, Zhou T, Lu J, Liu Y, Guo Q, et al. Interferon-based treatment is superior to nucleos(t)ide analog in reducing HBV-related hepatocellular carcinoma for chronic hepatitis B patients at high risk. Expert Opin Biol Ther. 2018;18(10):1085–94. doi:10.1080/14712598.2018.1518423.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence: Clinical Guidelines. Hepatitis B (chronic): diagnosis and management of chronic hepatitis B in children, young people and adults. London: National Institute for Health and Care Excellence (UK) Copyright © National Clinical Guideline Centre; 2013.
   Google Scholar
• Huang D, Wu D, Wang P, Wang Y, Yuan W, Hu D, Hu J, Wang Y, Tao R, Xiao F, et al. End-of-treatment HBcrAg and HBsAb levels identify durable functional cure after Peg-IFN-based therapy in patients with CHB. J Hepatol. 2022;77(1):42–54. doi:10.1016/j.jhep.2022.01.021.
   PubMed Web of Science ®Google Scholar
• Pan CQ, Li MH, Yi W, Zhang L, Lu Y, Hao HX, Wan G, Cao WH, Wang XY, Ran CP, et al. Outcome of Chinese patients with hepatitis B at 96 weeks after functional cure with IFN versus combination regimens. Liver Int. 2021;41(7):1498–508. doi:10.1111/liv.14801.
   PubMed Web of Science ®Google Scholar
• Brunskole Hummel I, Zitzmann A, Erl M, Wenzel JJ, Jilg W. Characteristics of immune memory 10–15 years after primary hepatitis B vaccination. Vaccine. 2016;34(5):636–42. doi:10.1016/j.vaccine.2015.12.033.
   PubMed Web of Science ®Google Scholar
• Wu Y, Liu Y, Lu J, Cao Z, Jin Y, Ma L, Geng N, Ren S, Zheng Y, Shen C, et al. Durability of interferon-induced hepatitis B surface antigen seroclearance. Clin Gastroenterol Hepatol. 2020;18(2):514–6.e512. doi:10.1016/j.cgh.2019.04.020.
   PubMed Web of Science ®Google Scholar
• Li MH, Yi W, Zhang L, Lu Y, Lu HH, Shen G, Wu SL, Hao HX, Gao YJ, Chang M, et al. Predictors of sustained functional cure in hepatitis B envelope antigen-negative patients achieving hepatitis B surface antigen seroclearance with interferon-alpha–based therapy. J Viral Hepat. 2019;26(Suppl 1):32–41. doi:10.1111/jvh.13151.
   PubMedGoogle Scholar
• Hou J, Wang G, Wang F, Cheng J, Ren H, Zhuang H, Sun J, Li L, Li J, Meng Q, et al. Guideline of prevention and treatment for chronic hepatitis B (2015 update). J Clin Transl Hepatol. 2017;5(4):297–318. doi:10.14218/jcth.2016.00019.
   PubMed Web of Science ®Google Scholar
• Yip TC, Wong GL, Wong VW, Tse YK, Lui GC, Lam KL, Chan HL. Durability of hepatitis B surface antigen seroclearance in untreated and nucleos(t)ide analogue-treated patients. J Hepatol. 2017;68(1):63–72. doi:10.1016/j.jhep.2017.09.018.
   Web of Science ®Google Scholar
• Wu Y, Wang X, Lin X, Shen C, Chen X. Quantitative of serum hepatitis B core antibody is a potential predictor of recurrence after interferon-induced hepatitis B surface antigen clearance. J Microbiol Immunol Infect. 2021;54(2):238–44. doi:10.1016/j.jmii.2019.09.004.
   PubMedGoogle Scholar
• Wang J, Chen X, Wu Y, Cao Z, Wang L, Huang H, Chen X, Lu F. Serum HBV RNA is a potential predictor of hepatitis B surface antigen reversion. Hepatol Commun. 2018;2(10):1168–71. doi:10.1002/hep4.1249.
   PubMed Web of Science ®Google Scholar
• Li M, Sun F, Bi X, Lin Y, Yang L, Lu Y, Zhang L, Wan G, Yi W, Zhao L, et al. Consolidation treatment needed for sustained HBsAg-negative response induced by interferon-alpha in HBeAg positive chronic hepatitis B patients. Virol Sin. 2022;37(3):390–97. doi:10.1016/j.virs.2022.03.001.
   PubMed Web of Science ®Google Scholar
• Liu F, Wang XW, Chen L, Hu P, Ren H, Hu HD. Systematic review with meta-analysis: development of hepatocellular carcinoma in chronic hepatitis B patients with hepatitis B surface antigen seroclearance. Aliment Pharmacol Ther. 2016;43(12):1253–61. doi:10.1111/apt.13634.
   PubMed Web of Science ®Google Scholar
• Bianchi FP, Gallone MS, Gallone MF, Larocca AMV, Vimercati L, Quarto M, Tafuri S. HBV seroprevalence after 25 years of universal mass vaccination and management of non-responders to the anti-Hepatitis B vaccine: an Italian study among medical students. J Viral Hepat. 2019;26(1):136–44. doi:10.1111/jvh.13001.
   PubMed Web of Science ®Google Scholar
• Dikici B, Bosnak M, Ucmak H, Dagli A, Ece A, Haspolat K. Failure of therapeutic vaccination using hepatitis B surface antigen vaccine in the immunotolerant phase of children with chronic hepatitis B infection. J Gastroenterol Hepatol. 2003;18(2):218–22. doi:10.1046/j.1440-1746.2003.02950.x.
   PubMed Web of Science ®Google Scholar
• Dikici B, Kalayci AG, Ozgenc F, Bosnak M, Davutoglu M, Ece A, Ozkan T, Ozeke T, Yagci RV, Haspolat K. Therapeutic vaccination in the immunotolerant phase of children with chronic hepatitis B infection. Pediatr Infect Dis J. 2003;22(4):345–49. doi:10.1097/01.inf.0000059443.49414.8b.
   PubMed Web of Science ®Google Scholar
• Yalcin K, Acar M, Degertekin H. Specific hepatitis B vaccine therapy in inactive HBsAg carriers: a randomized controlled trial. Infection. 2003;31(4):221–25. doi:10.1007/s15010-003-3187-1.
   PubMed Web of Science ®Google Scholar
• Cargill T, Barnes E. Therapeutic vaccination for treatment of chronic hepatitis B. Clin Exp Immunol. 2021;205(2):106–18. doi:10.1111/cei.13614.
   PubMed Web of Science ®Google Scholar
• Fung S, Choi HSJ, Gehring A, Janssen HLA. Getting to HBV cure: the promising paths forward. Hepatology. 2022;76(1):233–50. doi:10.1002/hep.32314.
   PubMed Web of Science ®Google Scholar
• Boni C, Janssen HLA, Rossi M, Yoon SK, Vecchi A, Barili V, Yoshida EM, Trinh H, Rodell TC, Laccabue D, et al. Combined GS-4774 and tenofovir therapy can improve HBV-specific T-cell responses in patients with chronic hepatitis. Gastroenterology. 2019;157(1):227–41.e227. doi:10.1053/j.gastro.2019.03.044.
   PubMed Web of Science ®Google Scholar
• Al Mahtab M, Akbar SMF, Aguilar JC, Guillen G, Penton E, Tuero A, Yoshida O, Hiasa Y, Onji M, Wong V. Treatment of chronic hepatitis B naïve patients with a therapeutic vaccine containing HBs and HBc antigens (a randomized, open and treatment controlled phase III clinical trial). PLoS One. 2018;13(8):e0201236. doi:10.1371/journal.pone.0201236.
   PubMed Web of Science ®Google Scholar
• Zhou C, Li C, Gong GZ, Wang S, Zhang JM, Xu DZ, Guo LM, Ren H, Xu M, Xie Q, et al. Analysis of immunological mechanisms exerted by HBsAg-HBIG therapeutic vaccine combined with Adefovir in chronic hepatitis B patients. Hum Vaccin Immunother. 2017;13(9):1989–96. doi:10.1080/21645515.2017.1335840.
   PubMed Web of Science ®Google Scholar
• Xu DZ, Zhao K, Guo LM, Li LJ, Xie Q, Ren H, Zhang JM, Xu M, Wang HF, Huang WX, et al. A randomized controlled phase IIb trial of antigen-antibody immunogenic complex therapeutic vaccine in chronic hepatitis B patients. PLoS One. 2008;3(7):e2565. doi:10.1371/journal.pone.0002565.
   PubMed Web of Science ®Google Scholar
• Phillips S, Chokshi S, Riva A, Evans A, Williams R, Naoumov NV. CD8 + T cell control of hepatitis B virus replication: direct comparison between cytolytic and noncytolytic functions. J Immunol. 2010;184(1):287–95. doi:10.4049/jimmunol.0902761.
   PubMed Web of Science ®Google Scholar